Literature DB >> 7565730

The cellular response to neuregulins is governed by complex interactions of the erbB receptor family.

D J Riese1, T M van Raaij, G D Plowman, G C Andrews, D F Stern.   

Abstract

Deregulated signaling by the four members of the epidermal growth factor receptor tyrosine kinase family (erbB family) is implicated in the genesis or progression of human cancers. However, efforts to analyze signaling by these receptors have been hampered by the diversity of ligands and extensive interreceptor cross talk. We have expressed the four human erbB family receptors, singly and in pairwise combinations, in a pro-B-lymphocyte cell line (Ba/F3) and investigated the range of interactions activated by the epidermal growth factor homology domain of the agonist neuregulin beta. The results provide the first comprehensive analysis of the response of this receptor family to a single peptide agonist. This peptide induced complex patterns of receptor tyrosine phosphorylation and regulation of Ba/F3 cell survival and proliferation. These data demonstrate the existence of several previously undocumented receptor interactions driven by neuregulin.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7565730      PMCID: PMC230829          DOI: 10.1128/MCB.15.10.5770

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  54 in total

1.  Improved retroviral vectors for gene transfer and expression.

Authors:  A D Miller; G J Rosman
Journal:  Biotechniques       Date:  1989-10       Impact factor: 1.993

2.  Comparison of the expression of the src gene of Rous sarcoma virus in vitro and in vivo.

Authors:  B M Sefton; K Beemon; T Hunter
Journal:  J Virol       Date:  1978-12       Impact factor: 5.103

3.  Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein.

Authors:  G Q Daley; D Baltimore
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

4.  Activation of cell growth by binding of Friend spleen focus-forming virus gp55 glycoprotein to the erythropoietin receptor.

Authors:  J P Li; A D D'Andrea; H F Lodish; D Baltimore
Journal:  Nature       Date:  1990-02-22       Impact factor: 49.962

5.  EGF receptor and erbB-2 tyrosine kinase domains confer cell specificity for mitogenic signaling.

Authors:  P P Di Fiore; O Segatto; W G Taylor; S A Aaronson; J H Pierce
Journal:  Science       Date:  1990-04-06       Impact factor: 47.728

6.  Transfer of functional EGF receptors to an IL3-dependent cell line.

Authors:  M K Collins; J Downward; A Miyajima; K Maruyama; K Arai; R C Mulligan
Journal:  J Cell Physiol       Date:  1988-11       Impact factor: 6.384

7.  Epidermal-growth-factor-dependent transformation by a human EGF receptor proto-oncogene.

Authors:  T J Velu; L Beguinot; W C Vass; M C Willingham; G T Merlino; I Pastan; D R Lowy
Journal:  Science       Date:  1987-12-04       Impact factor: 47.728

8.  Il-3-dependent mouse clones that express B-220 surface antigen, contain Ig genes in germ-line configuration, and generate B lymphocytes in vivo.

Authors:  R Palacios; M Steinmetz
Journal:  Cell       Date:  1985-07       Impact factor: 41.582

9.  Egf binding to its receptor triggers a rapid tyrosine phosphorylation of the erbB-2 protein in the mammary tumor cell line SK-BR-3.

Authors:  C R King; I Borrello; F Bellot; P Comoglio; J Schlessinger
Journal:  EMBO J       Date:  1988-06       Impact factor: 11.598

10.  EGF-stimulated tyrosine phosphorylation of p185neu: a potential model for receptor interactions.

Authors:  D F Stern; M P Kamps
Journal:  EMBO J       Date:  1988-04       Impact factor: 11.598

View more
  123 in total

Review 1.  Progesterone signaling and mammary gland morphogenesis.

Authors:  G Shyamala
Journal:  J Mammary Gland Biol Neoplasia       Date:  1999-01       Impact factor: 2.673

Review 2.  Roles of ErbB-3 and ErbB-4 in the physiology and pathology of the mammary gland.

Authors:  K L Carraway; C A Carraway; K L Carraway
Journal:  J Mammary Gland Biol Neoplasia       Date:  1997-04       Impact factor: 2.673

Review 3.  The ErbB signaling network: receptor heterodimerization in development and cancer.

Authors:  M A Olayioye; R M Neve; H A Lane; N E Hynes
Journal:  EMBO J       Date:  2000-07-03       Impact factor: 11.598

Review 4.  ErbB receptors and EGF-like ligands: cell lineage determination and oncogenesis through combinatorial signaling.

Authors:  R Pinkas-Kramarski; I Alroy; Y Yarden
Journal:  J Mammary Gland Biol Neoplasia       Date:  1997-04       Impact factor: 2.673

Review 5.  Neuregulin signaling via erbB receptor assemblies in the nervous system.

Authors:  Sean Murphy; Randy Krainock; Muly Tham
Journal:  Mol Neurobiol       Date:  2002-02       Impact factor: 5.590

6.  Neuregulin-3 (NRG3): a novel neural tissue-enriched protein that binds and activates ErbB4.

Authors:  D Zhang; M X Sliwkowski; M Mark; G Frantz; R Akita; Y Sun; K Hillan; C Crowley; J Brush; P J Godowski
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-02       Impact factor: 11.205

7.  The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors.

Authors:  L N Klapper; S Glathe; N Vaisman; N E Hynes; G C Andrews; M Sela; Y Yarden
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-27       Impact factor: 11.205

8.  Activation of HER4 by heparin-binding EGF-like growth factor stimulates chemotaxis but not proliferation.

Authors:  K Elenius; S Paul; G Allison; J Sun; M Klagsbrun
Journal:  EMBO J       Date:  1997-03-17       Impact factor: 11.598

9.  ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling.

Authors:  D Graus-Porta; R R Beerli; J M Daly; N E Hynes
Journal:  EMBO J       Date:  1997-04-01       Impact factor: 11.598

10.  Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesions.

Authors:  C-R Pradeep; A Zeisel; W J Köstler; M Lauriola; J Jacob-Hirsch; B Haibe-Kains; N Amariglio; N Ben-Chetrit; A Emde; I Solomonov; G Neufeld; M Piccart; I Sagi; C Sotiriou; G Rechavi; E Domany; C Desmedt; Y Yarden
Journal:  Oncogene       Date:  2011-12-05       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.